Tag Archives: R&D tax credit

Guest Blogspot – The UK Needs More Biotechnology Companies

Posted on May 17, 2011 by Barbara Arzymanow

The success of US biotechnology companies contrasts sharply with the disappointment in other countries. British companies valued by stock markets at more than about US $ 4 billion go in the FTSE 100 index. There are no biotechnology companies big … Continue reading →

Posted in Business, Drugs, Emerging technologies, Finance, Genetics, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , | 1 Comment

Guest Blogspot- Dept. of Health Consultation on Drug Pricing: “A new value-based approach to the pricing of branded medicines”

Posted on March 15, 2011 by Barbara Arzymanow

The Department of Health deadline for public submissions on pharmaceutical pricing is this Thursday. Many pitfalls must be avoided if the Government’s proposals are to form the basis of a successful drug pricing policy. Some problems are not easy to … Continue reading →

Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, NHS, Pharma, Policy, Research, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | 3 Comments

Guest Blogspote: How to encourage pharmaceutical R&D

Posted on February 15, 2011 by Barbara Arzymanow

Politicians should only attempt the possible. We must recognise what we cannot do. The UK Government alone cannot influence the direction of R&D significantly. The sums of money involved are so vast that R&D only makes sense in a global … Continue reading →

Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, Health Bill, Hospitals, Innovation, NHS, Pharma, Policy, Research, Uncategorized, White Paper | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment